蘇利股份(603585.SH):與永達藥業就原料藥及醫藥中間體生產項目展開合作 擬設立永達蘇利
格隆匯 12 月 28日丨蘇利股份(603585.SH)公佈,公司全資子公司蘇利製藥與江蘇永達藥業有限公司(“永達藥業”)就原料藥及醫藥中間體生產項目展開合作,蘇利製藥、永達藥業與自然人李萍於2020年12月28日簽訂合資合同,擬在大連長興島成立永達蘇利。
永達蘇利的註冊資本為1億元人民幣,其中蘇利製藥以貨幣方式認繳出資4000萬元人民幣,持有永達蘇利40%的股權,永達藥業以貨幣方式認繳出資5100萬元人民幣,持有永達蘇利51%的股權,李萍以貨幣方式認繳出資900萬元人民幣,持有永達蘇利9.00%的股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.